Organigram Holdings

OGI

Market cap $214M

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, today announced the expansion of its innovation investment in Phylos Bioscience Inc. (“Phylos”), securing Organigram's position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos' autoflower genetics pipeline, including preferential economic terms and long-ter.

Organigram reported solid Q4 earnings, highlighted by achieving a record gross margin and issuing a net revenue guidance implying sustained double-digit organic growth. Quebec's recent vape launch could boost Organigram's Canadian market share, while consumer shift to quality experiences could boost sales of higher-margin liquid diamond vapes. Organigram's expanded capacity and adoption of seed-based cultivation reduce its cost per gram while offering opportunities to increase exports to higher-margin international markets.

Cannabis stocks sold off this week following President Trump's Executive Order directing marijuana's reclassification to Schedule III for increased medical and cannabidiol research. The sharp selloff highlights how fragile sentiment in cannabis stock remains, even amid policy progress. Further volatility is possible if regulatory implementation drags on or if broader market risk appetite weakens.

Organigram Global Inc. (OGI:CA) Q4 2025 Earnings Call Transcript

OrganiGram (OGI) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.04 per share a year ago.

TORONTO--(BUSINESS WIRE)--Organigram Global Inc (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 recreational cannabis company by market share2, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 (“Q4 Fiscal 2025” or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS Gross Revenue: $123.3 million (+76% year-over-year). Net Reven.

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, announced today it will report earnings results for its fourth quarter fiscal 2025 ended September 30, 2025, on Tuesday, December 16, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, December 16, 2025 Time: 8:00 am Eastern Time To register for the conference cal.

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company's new Chief Executive Officer (CEO). Mr. Yamanaka is expected to assume the role effective on or about January 15, 2026. Mr. Yamanaka will also join the Company's board of di.

Organigram upgraded to Buy and Village Farms downgraded to Strong Sell, reflecting shifts in fundamentals and valuation. OGI stands out for its strong balance sheet, strategic partnership with BTI, and potential for margin expansion, despite near-term risks. VFF has surged 356% year-to-date, but concerns over its rapid run-up, lack of guidance, and potential Texas disappointment justify a cautious outlook.

Four cannabis stocks are demonstrating significant technical momentum, seemingly undeterred by new regulatory headwinds from Washington.